Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entasis Therapeutics Holdings Inc.ETTX · Entity 16036 | Director | June 19, 2019 | June 21, 2019 |
| Praxis Precision Medicines, Inc.PRAX · Entity 3538 | Director | June 10, 2026 | June 12, 2026 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | June 05, 2026 | June 08, 2026 |
| Zoetis Inc.ZTS · Entity 679 | Director | March 09, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entasis Therapeutics Holdings Inc.
Report date June 19, 2019 · Filed June 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.12 · Expires 2029-06-18 | Direct | 7,500 |
Reported balance
After 2019-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-19 · Grant · Acquired 7,500 · Balance 7,500 F1: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date.
Praxis Precision Medicines, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,559 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 1,371 · Balance 1,559 F1: Mr. Norden was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.66 · Expires 2036-06-10 | Direct | 648 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 648 · Balance 648 F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Norden was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.
Royalty Pharma plc
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 196,348 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 4,545 · Balance 196,348 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
Zoetis Inc.
Report date March 09, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-03-09 transaction · row 1
1 source rowRow 1 · 2026-03-09 · Gift · Disposed 1,213 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy personal trust | 7,071.1922 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,071.1922 F1: On March 9, 2026, the reporting person transferred 1,213 shares of Zoetis common stock to a trust of which the reporting person is a trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy daughter's trust | 5,548 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,548 |
| Common StockSEC Table I · non-derivative | IndirectBy son's trust | 5,548 |
Reported balance
Holding disclosure · report date 2026-03-09 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,548 |
Filing footnotes · ownership attribution and instrument terms
F1: On March 9, 2026, the reporting person transferred 1,213 shares of Zoetis common stock to a trust of which the reporting person is a trustee.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NanoString Technologies Inc
Report date May 06, 2024 · Filed May 08, 2024
Section 16 reporting ended · disclosed 2024-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,552 |
Reported balance
After 2024-05-06 transaction · row 1
1 source rowRow 1 · 2024-05-06 · Exercise / conversion · Acquired 41,133 · Balance 88,552 F1: The shares have not been delivered to the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-06 · Exercise / conversion · Disposed 41,133 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F3: Pursuant to the terms of the award, as a result of the closing of the sale of substantially all of the assets of the Company to Bruker Corporation, which constituted a "Change of Control" under the terms of the RSU award agreement, the vesting of the RSUs accelerated. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares have not been delivered to the reporting person.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
F3: Pursuant to the terms of the award, as a result of the closing of the sale of substantially all of the assets of the Company to Bruker Corporation, which constituted a "Change of Control" under the terms of the RSU award agreement, the vesting of the RSUs accelerated.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2017 Filed Feb 16, 2017 17:06 UTC | Zoetis Inc. ZTS · Entity 679 | GrantRestricted Stock Unit · Derivative | 3,635 | $55.02 | $199,997.70 |
DisclosureSEC source: 0001555280-17-000059 · wf-form4_148728280604852.xml · derivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,476.5959 Underlying: Common Stock · 3,635 shares Expires not disclosed F1 · security: Represents restricted stock units granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan, and dividend equivalent units automatically issued thereon (collectively, "RSUs"). Restricted stock units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. Dividend equivalent units vest and are settled in shares of Zoetis common stock on the third anniversary of the date of grant of the underlying restricted stock units, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zoetis Inc. common stock. F3 · derivative.exercise_date: Each RSU will vest and be settled in shares of Zoetis Inc. common stock on the third anniversary of the date of grant, subject to the reporting person's continued service through such vesting date and subject to earlier vesting and settlement upon certain specific events. F4 · derivative.expiration_date: Not applicable. F5 · balance_after: The RSUs vest as follows: 3,745.3906 RSUs will vest on February 27, 2018; 4,096.2053 RSUs will vest on February 19, 2019; and 3,635 RSUs will vest on February 14, 2020. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 18:09 UTC | NanoString Technologies Inc NSTG · Entity 15988 | GrantStock Option (Right to Buy) · Derivative | 8,611 | $0.00 Strike: $22.30 | $0.00 |
DisclosureSEC source: 0001209191-17-001348 · doc4.xml · derivative · entry 1 Norden Gregory · CIK 0001405104 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,611 Underlying: Common Stock · 8,611 shares Expires 2026-12-31 F1 · derivative.exercise_date: 100% of the shares subject to the Option vest on the one year anniversary of January 1, 2017. The vesting of shares subject to the Option will accelerate in full upon a "change in control" as defined in the 2013 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.